Halozyme Therapeutics, Inc. (NASDAQ: HALO) Stock Competitors & Peer Comparison
See HALO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HALO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HALO | $100.27 | -0.40% | 11.4B | 18.71 | $5.36 | N/A |
| VRTX | $538.60 | -0.74% | 136.6B | 28.30 | $19.03 | N/A |
| REGN | $955.47 | +0.45% | 98.8B | 20.94 | $45.63 | +0.38% |
| MRNA | $223.37 | -3.45% | 90.4B | -27.41 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $960.04 | -2.17% | 60B | 34.62 | $27.73 | N/A |
| ONC | $416.54 | +0.14% | 44.5B | 73.33 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $172.29 | -2.30% | 37.3B | -19.53 | -$8.82 | N/A |
| RVMDW | $7.68 | -5.83% | 35.9B | -0.87 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
HALO vs VRTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, VRTX has a market cap of 136.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while VRTX trades at $538.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas VRTX's P/E ratio is 28.30. In terms of profitability, HALO's ROE is +5.44%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, HALO is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
HALO vs REGN Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, REGN has a market cap of 98.8B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while REGN trades at $955.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas REGN's P/E ratio is 20.94. In terms of profitability, HALO's ROE is +5.44%, compared to REGN's ROE of +0.15%. Regarding short-term risk, HALO is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for HALO.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
HALO vs MRNA Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, MRNA has a market cap of 90.4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while MRNA trades at $223.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas MRNA's P/E ratio is -27.41. In terms of profitability, HALO's ROE is +5.44%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, HALO is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for HALO.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
HALO vs VRNA Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas VRNA's P/E ratio is -102.80. In terms of profitability, HALO's ROE is +5.44%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, HALO is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for HALO.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
HALO vs ARGX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ARGX has a market cap of 60B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ARGX trades at $960.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ARGX's P/E ratio is 34.62. In terms of profitability, HALO's ROE is +5.44%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, HALO is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
HALO vs ONC Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ONC has a market cap of 44.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ONC trades at $416.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ONC's P/E ratio is 73.33. In terms of profitability, HALO's ROE is +5.44%, compared to ONC's ROE of +0.18%. Regarding short-term risk, HALO is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
HALO vs SGEN Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas SGEN's P/E ratio is -57.19. In terms of profitability, HALO's ROE is +5.44%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, HALO is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for HALO.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
HALO vs RVMD Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, RVMD has a market cap of 37.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while RVMD trades at $172.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas RVMD's P/E ratio is -19.53. In terms of profitability, HALO's ROE is +5.44%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, HALO is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for HALO.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
HALO vs RVMDW Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, RVMDW has a market cap of 35.9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while RVMDW trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas RVMDW's P/E ratio is -0.87. In terms of profitability, HALO's ROE is +5.44%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, HALO is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for HALO.Check RVMDW's competition here
Genmab A/S (NASDAQ: GMAB)
HALO vs GMAB Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, GMAB has a market cap of 31.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while GMAB trades at $51.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas GMAB's P/E ratio is 38.71. In terms of profitability, HALO's ROE is +5.44%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, HALO is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for HALO.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
HALO vs ROIV Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ROIV has a market cap of 28.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ROIV trades at $39.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ROIV's P/E ratio is -37.61. In terms of profitability, HALO's ROE is +5.44%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, HALO is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
HALO vs INSM Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, INSM has a market cap of 26.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while INSM trades at $121.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas INSM's P/E ratio is -42.96. In terms of profitability, HALO's ROE is +5.44%, compared to INSM's ROE of -0.83%. Regarding short-term risk, HALO is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for HALO.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
HALO vs UTHR Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while UTHR trades at $591.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas UTHR's P/E ratio is 21.15. In terms of profitability, HALO's ROE is +5.44%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, HALO is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for HALO.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
HALO vs INCY Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, INCY has a market cap of 24.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while INCY trades at $120.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas INCY's P/E ratio is 16.26. In terms of profitability, HALO's ROE is +5.44%, compared to INCY's ROE of +0.07%. Regarding short-term risk, HALO is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for HALO.Check INCY's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
HALO vs ALNY Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ALNY has a market cap of 22.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ALNY trades at $165.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ALNY's P/E ratio is 8.34. In terms of profitability, HALO's ROE is +5.44%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, HALO is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
HALO vs BNTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, BNTX has a market cap of 21.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while BNTX trades at $85.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas BNTX's P/E ratio is -11.10. In terms of profitability, HALO's ROE is +5.44%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, HALO is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
HALO vs BGNE Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas BGNE's P/E ratio is -22.55. In terms of profitability, HALO's ROE is +5.44%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, HALO is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for HALO.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
HALO vs DNA-WT Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, HALO's ROE is +5.44%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, HALO is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
HALO vs ASND Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ASND has a market cap of 18.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ASND trades at $275.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ASND's P/E ratio is -113.80. In terms of profitability, HALO's ROE is +5.44%, compared to ASND's ROE of +1.08%. Regarding short-term risk, HALO is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
HALO vs EXEL Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, EXEL has a market cap of 17.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while EXEL trades at $69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas EXEL's P/E ratio is 19.71. In terms of profitability, HALO's ROE is +5.44%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, HALO is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for HALO.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
HALO vs NBIX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while NBIX trades at $167.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas NBIX's P/E ratio is 24.19. In terms of profitability, HALO's ROE is +5.44%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, HALO is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
HALO vs JAZZ Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, JAZZ has a market cap of 15.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while JAZZ trades at $241.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas JAZZ's P/E ratio is 9.01. In terms of profitability, HALO's ROE is +5.44%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, HALO is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for HALO.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
HALO vs BBIO Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, BBIO has a market cap of 15.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while BBIO trades at $78.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas BBIO's P/E ratio is -25.76. In terms of profitability, HALO's ROE is +5.44%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, HALO is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for HALO.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
HALO vs KRTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas KRTX's P/E ratio is -28.09. In terms of profitability, HALO's ROE is +5.44%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, HALO is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
HALO vs TECH Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while TECH trades at $72.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas TECH's P/E ratio is 37.53. In terms of profitability, HALO's ROE is +5.44%, compared to TECH's ROE of +0.08%. Regarding short-term risk, HALO is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for HALO.Check TECH's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
HALO vs SMMT Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, SMMT has a market cap of 11.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while SMMT trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas SMMT's P/E ratio is -12.63. In terms of profitability, HALO's ROE is +5.44%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, HALO is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check SMMT's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
HALO vs RNAM Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas RNAM's P/E ratio is -17.39. In terms of profitability, HALO's ROE is +5.44%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, HALO is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for HALO.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
HALO vs BMRN Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while BMRN trades at $57.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas BMRN's P/E ratio is 27.51. In terms of profitability, HALO's ROE is +5.44%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, HALO is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for HALO.Check BMRN's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
HALO vs KYMR Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, KYMR has a market cap of 10.9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while KYMR trades at $127.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas KYMR's P/E ratio is -35.24. In terms of profitability, HALO's ROE is +5.44%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, HALO is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for HALO.Check KYMR's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
HALO vs PCVX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while PCVX trades at $63.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas PCVX's P/E ratio is -8.31. In terms of profitability, HALO's ROE is +5.44%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, HALO is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check PCVX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
HALO vs MDGL Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while MDGL trades at $427.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas MDGL's P/E ratio is -33.39. In terms of profitability, HALO's ROE is +5.44%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, HALO is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for HALO.Check MDGL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
HALO vs SYRE Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, SYRE has a market cap of 9.9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while SYRE trades at $104.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas SYRE's P/E ratio is -53.33. In terms of profitability, HALO's ROE is +5.44%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, HALO is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for HALO.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
HALO vs TGTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, TGTX has a market cap of 9.8B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while TGTX trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas TGTX's P/E ratio is 23.37. In terms of profitability, HALO's ROE is +5.44%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, HALO is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check TGTX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
HALO vs RXDX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas RXDX's P/E ratio is -56.47. In terms of profitability, HALO's ROE is +5.44%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, HALO is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check RXDX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
HALO vs PRAX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while PRAX trades at $328.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas PRAX's P/E ratio is -25.38. In terms of profitability, HALO's ROE is +5.44%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, HALO is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check PRAX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
HALO vs NUVL Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas NUVL's P/E ratio is -21.79. In terms of profitability, HALO's ROE is +5.44%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, HALO is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for HALO.Check NUVL's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
HALO vs KRYS Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while KRYS trades at $305.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas KRYS's P/E ratio is 38.25. In terms of profitability, HALO's ROE is +5.44%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, HALO is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check KRYS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
HALO vs CRNX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CRNX's P/E ratio is -16.86. In terms of profitability, HALO's ROE is +5.44%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, HALO is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
HALO vs IMGN Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas IMGN's P/E ratio is -111.55. In terms of profitability, HALO's ROE is +5.44%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, HALO is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for HALO.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
HALO vs PTGX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while PTGX trades at $130.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas PTGX's P/E ratio is 127.14. In terms of profitability, HALO's ROE is +5.44%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, HALO is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
HALO vs APGE Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas APGE's P/E ratio is -31.19. In terms of profitability, HALO's ROE is +5.44%, compared to APGE's ROE of -0.30%. Regarding short-term risk, HALO is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for HALO.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
HALO vs BPMC Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas BPMC's P/E ratio is -51.58. In terms of profitability, HALO's ROE is +5.44%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, HALO is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for HALO.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
HALO vs CERE Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CERE's P/E ratio is -16.47. In terms of profitability, HALO's ROE is +5.44%, compared to CERE's ROE of -0.72%. Regarding short-term risk, HALO is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CERE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
HALO vs RYTM Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, RYTM has a market cap of 8B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while RYTM trades at $115.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas RYTM's P/E ratio is -36.98. In terms of profitability, HALO's ROE is +5.44%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, HALO is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for HALO.Check RYTM's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
HALO vs CYTK Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CYTK trades at $56.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CYTK's P/E ratio is -7.77. In terms of profitability, HALO's ROE is +5.44%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, HALO is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for HALO.Check CYTK's competition here
Abivax S.A. (NASDAQ: ABVX)
HALO vs ABVX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ABVX trades at $87.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ABVX's P/E ratio is -14.35. In terms of profitability, HALO's ROE is +5.44%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, HALO is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ABVX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
HALO vs AXSM Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, AXSM has a market cap of 7.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while AXSM trades at $141.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas AXSM's P/E ratio is -36.99. In terms of profitability, HALO's ROE is +5.44%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, HALO is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for HALO.Check AXSM's competition here
Metsera, Inc. (NASDAQ: MTSR)
HALO vs MTSR Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas MTSR's P/E ratio is -23.58. In terms of profitability, HALO's ROE is +5.44%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, HALO is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for HALO.Check MTSR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
HALO vs TWST Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, TWST has a market cap of 7.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while TWST trades at $111.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas TWST's P/E ratio is -50.27. In terms of profitability, HALO's ROE is +5.44%, compared to TWST's ROE of -0.23%. Regarding short-term risk, HALO is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for HALO.Check TWST's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
HALO vs ORKA Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ORKA trades at $105.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ORKA's P/E ratio is -54.30. In terms of profitability, HALO's ROE is +5.44%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, HALO is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ORKA's competition here
Immunovant, Inc. (NASDAQ: IMVT)
HALO vs IMVT Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, IMVT has a market cap of 7.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while IMVT trades at $34.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas IMVT's P/E ratio is -12.12. In terms of profitability, HALO's ROE is +5.44%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, HALO is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
HALO vs TXG Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, TXG has a market cap of 7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while TXG trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas TXG's P/E ratio is -98.63. In terms of profitability, HALO's ROE is +5.44%, compared to TXG's ROE of -0.08%. Regarding short-term risk, HALO is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for HALO.Check TXG's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
HALO vs KOD Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, KOD has a market cap of 7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while KOD trades at $111.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas KOD's P/E ratio is -26.66. In terms of profitability, HALO's ROE is +5.44%, compared to KOD's ROE of -2.88%. Regarding short-term risk, HALO is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for HALO.Check KOD's competition here
Merus N.V. (NASDAQ: MRUS)
HALO vs MRUS Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas MRUS's P/E ratio is -17.05. In terms of profitability, HALO's ROE is +5.44%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, HALO is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for HALO.Check MRUS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
HALO vs ARWR Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ARWR has a market cap of 6.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ARWR trades at $47.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ARWR's P/E ratio is -21.24. In terms of profitability, HALO's ROE is +5.44%, compared to ARWR's ROE of -0.75%. Regarding short-term risk, HALO is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ARWR's competition here
Arcellx, Inc. (NASDAQ: ACLX)
HALO vs ACLX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ACLX's P/E ratio is -28.27. In terms of profitability, HALO's ROE is +5.44%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, HALO is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
HALO vs CGON Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CGON trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CGON's P/E ratio is -27.66. In terms of profitability, HALO's ROE is +5.44%, compared to CGON's ROE of -0.25%. Regarding short-term risk, HALO is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for HALO.Check CGON's competition here
Belite Bio, Inc (NASDAQ: BLTE)
HALO vs BLTE Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while BLTE trades at $164.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas BLTE's P/E ratio is -87.89. In terms of profitability, HALO's ROE is +5.44%, compared to BLTE's ROE of -0.17%. Regarding short-term risk, HALO is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for HALO.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
HALO vs CAI Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CAI has a market cap of 6.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CAI trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CAI's P/E ratio is 64.74. In terms of profitability, HALO's ROE is +5.44%, compared to CAI's ROE of +0.16%. Regarding short-term risk, HALO is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for HALO.Check CAI's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
HALO vs RETA Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas RETA's P/E ratio is -66.29. In terms of profitability, HALO's ROE is +5.44%, compared to RETA's ROE of +0.47%. Regarding short-term risk, HALO is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for HALO.Check RETA's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
HALO vs IBRX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, IBRX has a market cap of 6.4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while IBRX trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas IBRX's P/E ratio is -6.21. In terms of profitability, HALO's ROE is +5.44%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, HALO is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check IBRX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
HALO vs CNTA Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CNTA's P/E ratio is -22.63. In terms of profitability, HALO's ROE is +5.44%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, HALO is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
HALO vs LGND Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, LGND has a market cap of 6.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while LGND trades at $308.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas LGND's P/E ratio is 33.90. In terms of profitability, HALO's ROE is +5.44%, compared to LGND's ROE of +0.05%. Regarding short-term risk, HALO is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for HALO.Check LGND's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
HALO vs MIRM Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while MIRM trades at $93.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas MIRM's P/E ratio is -6.46. In terms of profitability, HALO's ROE is +5.44%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, HALO is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for HALO.Check MIRM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
HALO vs TERN Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas TERN's P/E ratio is -51.41. In terms of profitability, HALO's ROE is +5.44%, compared to TERN's ROE of -0.14%. Regarding short-term risk, HALO is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for HALO.Check TERN's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
HALO vs CDTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CDTX's P/E ratio is -19.77. In terms of profitability, HALO's ROE is +5.44%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, HALO is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
HALO vs ABCM Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, HALO's ROE is +5.44%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, HALO is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
HALO vs ISEE Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ISEE's P/E ratio is -22.44. In terms of profitability, HALO's ROE is +5.44%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, HALO is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
HALO vs ERAS Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ERAS trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ERAS's P/E ratio is -16.84. In terms of profitability, HALO's ROE is +5.44%, compared to ERAS's ROE of -0.62%. Regarding short-term risk, HALO is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
HALO vs MANE Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, MANE has a market cap of 5.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while MANE trades at $129.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas MANE's P/E ratio is -41.27. In terms of profitability, HALO's ROE is +5.44%, compared to MANE's ROE of -0.20%. Regarding short-term risk, HALO is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for HALO.Check MANE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
HALO vs PTCT Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while PTCT trades at $63.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas PTCT's P/E ratio is -45.35. In terms of profitability, HALO's ROE is +5.44%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, HALO is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for HALO.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
HALO vs SRRK Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while SRRK trades at $43.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas SRRK's P/E ratio is -12.52. In terms of profitability, HALO's ROE is +5.44%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, HALO is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for HALO.Check SRRK's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
HALO vs APLS Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas APLS's P/E ratio is 38.35. In terms of profitability, HALO's ROE is +5.44%, compared to APLS's ROE of +0.40%. Regarding short-term risk, HALO is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for HALO.Check APLS's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
HALO vs DNTH Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, DNTH has a market cap of 5.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while DNTH trades at $91.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas DNTH's P/E ratio is -22.12. In terms of profitability, HALO's ROE is +5.44%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, HALO is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for HALO.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
HALO vs COGT Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, COGT has a market cap of 5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while COGT trades at $28.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas COGT's P/E ratio is -13.54. In terms of profitability, HALO's ROE is +5.44%, compared to COGT's ROE of -0.71%. Regarding short-term risk, HALO is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check COGT's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
HALO vs EWTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while EWTX trades at $45.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas EWTX's P/E ratio is -24.83. In terms of profitability, HALO's ROE is +5.44%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, HALO is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check EWTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
HALO vs TVTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, TVTX has a market cap of 4.9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while TVTX trades at $50.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas TVTX's P/E ratio is -112.56. In terms of profitability, HALO's ROE is +5.44%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, HALO is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check TVTX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
HALO vs IONS Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, IONS has a market cap of 4.8B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while IONS trades at $29.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas IONS's P/E ratio is -8.89. In terms of profitability, HALO's ROE is +5.44%, compared to IONS's ROE of -1.20%. Regarding short-term risk, HALO is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check IONS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
HALO vs ADPT Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ADPT trades at $29.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ADPT's P/E ratio is -70.83. In terms of profitability, HALO's ROE is +5.44%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, HALO is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
HALO vs FOLD Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas FOLD's P/E ratio is -161.00. In terms of profitability, HALO's ROE is +5.44%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, HALO is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for HALO.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
HALO vs AKRO Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas AKRO's P/E ratio is -14.57. In terms of profitability, HALO's ROE is +5.44%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, HALO is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for HALO.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
HALO vs ALPN Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ALPN's P/E ratio is -101.52. In terms of profitability, HALO's ROE is +5.44%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, HALO is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for HALO.Check ALPN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
HALO vs DFTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, DFTX has a market cap of 4.4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while DFTX trades at $32.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas DFTX's P/E ratio is N/A. In terms of profitability, HALO's ROE is +5.44%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, HALO is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check DFTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
HALO vs TNGX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while TNGX trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas TNGX's P/E ratio is -30.72. In terms of profitability, HALO's ROE is +5.44%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, HALO is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
HALO vs OPT Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas OPT's P/E ratio is -1.52. In terms of profitability, HALO's ROE is +5.44%, compared to OPT's ROE of +1.18%. Regarding short-term risk, HALO is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for HALO.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
HALO vs PRTC Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas PRTC's P/E ratio is -3.78. In terms of profitability, HALO's ROE is +5.44%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, HALO is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for HALO.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
HALO vs MRTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas MRTX's P/E ratio is -4.82. In terms of profitability, HALO's ROE is +5.44%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, HALO is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check MRTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
HALO vs CRSP Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CRSP has a market cap of 4.1B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CRSP trades at $42.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CRSP's P/E ratio is -8.87. In terms of profitability, HALO's ROE is +5.44%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, HALO is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for HALO.Check CRSP's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
HALO vs RLAY Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while RLAY trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas RLAY's P/E ratio is -11.52. In terms of profitability, HALO's ROE is +5.44%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, HALO is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for HALO.Check RLAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
HALO vs XENE Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, XENE has a market cap of 4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while XENE trades at $40.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas XENE's P/E ratio is -8.61. In terms of profitability, HALO's ROE is +5.44%, compared to XENE's ROE of -0.40%. Regarding short-term risk, HALO is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for HALO.Check XENE's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
HALO vs TARS Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, TARS has a market cap of 4B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while TARS trades at $80.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas TARS's P/E ratio is -73.65. In terms of profitability, HALO's ROE is +5.44%, compared to TARS's ROE of -2.46%. Regarding short-term risk, HALO is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for HALO.Check TARS's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
HALO vs AMLX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, AMLX has a market cap of 3.9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while AMLX trades at $30.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas AMLX's P/E ratio is -20.19. In terms of profitability, HALO's ROE is +5.44%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, HALO is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check AMLX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
HALO vs CPRX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CPRX's P/E ratio is 17.49. In terms of profitability, HALO's ROE is +5.44%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, HALO is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
HALO vs ABCL Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ABCL trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ABCL's P/E ratio is -21.28. In terms of profitability, HALO's ROE is +5.44%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, HALO is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ABCL's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
HALO vs RYZB Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas RYZB's P/E ratio is -57.86. In terms of profitability, HALO's ROE is +5.44%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, HALO is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for HALO.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
HALO vs CBAY Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas CBAY's P/E ratio is -32.81. In terms of profitability, HALO's ROE is +5.44%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, HALO is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for HALO.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
HALO vs VKTX Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while VKTX trades at $29.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas VKTX's P/E ratio is -5.41. In terms of profitability, HALO's ROE is +5.44%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, HALO is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for HALO.Check VKTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
HALO vs ELVN Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while ELVN trades at $48.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas ELVN's P/E ratio is -29.22. In terms of profitability, HALO's ROE is +5.44%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, HALO is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for HALO.Check ELVN's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
HALO vs IOVA Comparison November 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HALO stands at 11.4B. In comparison, IOVA has a market cap of 3.6B. Regarding current trading prices, HALO is priced at $100.27 on the NASDAQ, while IOVA trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HALO currently has a P/E ratio of 18.71, whereas IOVA's P/E ratio is -10.63. In terms of profitability, HALO's ROE is +5.44%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, HALO is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for HALO.Check IOVA's competition here